Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Bladder cancer

Angiogenesis as a therapeutic target in urothelial carcinoma

Nature Reviews Urology volume 13, pages 306–307 (2016)Cite this article

Subjects

Angiogenesis has not yet been validated as a therapeutic target in advanced urothelial carcinoma. However, a recent phase II trial has suggested that ramucirumab — a vascular endothelial growth factor (VEGF) receptor-2 antibody — combined with second-line docetaxel, might be beneficial.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bellmunt, J. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 27, 4454–4461 (2009).

    Article  CAS  Google Scholar 

  2. McCaffrey, J. A. et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J. Clin. Oncol. 15, 1853–1857 (1997).

    Article  CAS  Google Scholar 

  3. Petrylak, D. P. et al. Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: an open-label, three-arm, randomized controlled phase ii trial. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2015.65.0218 (2016).

  4. Sonpavde, G. et al. Improved 5-factor prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. J. Urol. 195, 277–282 (2016).

    Article  Google Scholar 

  5. Agarwal, N. et al. Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin. Genitourin. Cancer 12, 130–137 (2014).

    Article  Google Scholar 

  6. Grivas, P. D. et al. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer 120, 692–701 (2014).

    Article  CAS  Google Scholar 

  7. Powles, T. et al. PLUTO: a randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours [abstract]. J. Clin. Oncol. 34 (Suppl. 2S), 430 (2016).

    Article  Google Scholar 

  8. Choueiri, T. K. et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J. Clin. Oncol. 30, 507–512 (2012).

    Article  CAS  Google Scholar 

  9. Krege, S. et al. Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05). BJU Int. 113, 429–436 (2014).

    Article  CAS  Google Scholar 

  10. Apolo, A. B. et al. Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma [abstract]. J. Clin. Oncol. 32 (Suppl. 5S), 4501 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Guru Sonpavde is at the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, 1720 2nd Avenue South, Birmingham, Alabama 35294, USA.,

    Guru Sonpavde

  2. Joaquim Bellmunt is at the Dana Farber Cancer Institute and Harvard Medical School, 450 Brookline Avenue, Boston, Massachusetts 02215, USA.,

    Joaquim Bellmunt

Authors
  1. Guru Sonpavde
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joaquim Bellmunt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guru Sonpavde.

Ethics declarations

Competing interests

G.S. declares research support from Onyx, Bayer, Merck, Celgene, Pfizer, and Boehringer-Ingelheim; and that he has acted as advisory board/consultant for Merck, Genentech, Sanofi, Bayer, Pfizer, Agensys, Novartis, and Argos. J.B. declares that he has acted as a consultant for Pierre Fabre, Astellas, Pfizer, Genentech, and Merck; and that he has received research funding from Takeda and Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sonpavde, G., Bellmunt, J. Angiogenesis as a therapeutic target in urothelial carcinoma. Nat Rev Urol 13, 306–307 (2016). https://doi.org/10.1038/nrurol.2016.69

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2016.69

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer